An interesting point made by US researchers in favour of early referrals for deep brain stimulation therapy:
Researchers looked back to a 2004 study, which found that just 5% of referrals then were good candidates; they compared their new figures and surmised that referring physicians have increased their awareness and acceptance of deep brain stimulation. But physicians still often refer patients for this therapy before other treatment options have been exhausted or because they have unrealistically high expectations for it, said Michele Tagliati, director of the Movement Disorders Program at Cedars-Sinai’s Department of Neurology.
Analysing the referral sources ― movement disorder specialists, primary care physicians, general neurologists, other physicians and patients ― the researchers found that movement disorder specialists referred more patients and most were good therapy candidates. Over the four-year study period, which ended in late 2009, researchers noted that the number of patients referred for deep brain stimulation therapy at earlier stages of the disease increased. “The study does not address this change specifically and we have no proof, but we speculate that doctors became more liberal in sending patients for surgery for deep brain stimulation,” Tagliati said. “Maybe they are accepting this therapy more and sending patients earlier for it instead of at the very end stage of disease. While doctors may be sending some patients too early to be treated immediately with deep brain stimulation therapy, it is better to see these patients too early than too late. As long as they are evaluated in a responsible, reputable movement disorders centre, they can be reevaluated months or even years later and have the surgery appropriately timed. It is not always clear exactly what is the right time for this therapy, but especially for Parkinson’s disease, if the patient is amenable to medication changes, it is not appropriate to jump to the surgery right away.” Deep brain stimulation was approved by the Food and Drug Administration for essential tremor in 1997, Parkinson’s disease in 2002, dystonia in 2003 and extreme cases of obsessive-compulsive disorder in 2009″ |
Source: BMJ